TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis
Bo Chen1, Shan Liu, Xue-Li Wang
1Department of Geriatrics, First Affiliated Hospital, Nanjing Medical University, Nanjing, China. chenbo361du@163.com
European Journal of Cancer (Oxford, England : 1990)
|August 1, 2009
Summary
This meta-analysis found that tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) polymorphisms rs2230229 (A1322G) and rs20576 (A683C) are associated with increased cancer risk. The TRAIL-R1 C626G polymorphism showed a marginal association with cancer susceptibility.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Published data on the association between TRAIL-R1 (DR4) polymorphisms (rs20575, rs2230229, rs20576) and cancer risk are inconclusive.
- Tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) plays a role in apoptosis and cancer development.
Purpose of the Study:
- To perform a meta-analysis to precisely estimate the relationship between TRAIL-R1 polymorphisms and cancer risk.
- To investigate the association of specific TRAIL-R1 polymorphisms (C626G, A1322G, A683C) with overall cancer susceptibility.
Main Methods:
- A meta-analysis was conducted on nine studies involving 2941 cases and 3358 controls for C626G, 736 cases and 668 controls for A1322G, and 1550 cases and 2257 controls for A683C.
- Statistical analysis included various genetic models (homozygote, dominant, recessive) and subgroup analysis by control source.
Main Results:
- The TRAIL-R1 C626G polymorphism showed no overall association with cancer risk, but a reduced risk was observed in subgroup analysis with population-based controls.
- The TRAIL-R1 A1322G polymorphism was significantly associated with elevated cancer risk across different genetic models.
- The TRAIL-R1 A683C polymorphism also demonstrated a significantly increased cancer risk in homozygote and dominant models.
Conclusions:
- TRAIL-R1 C626G polymorphism has a marginal association with cancer susceptibility.
- TRAIL-R1 A1322G (G allele) and A683C (C allele) polymorphisms are associated with an increased risk for cancer.
- These findings highlight the potential role of specific TRAIL-R1 polymorphisms in cancer development.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...